Articles tagged "Malignancy"

2015 American Transplant Congress
Everolimus-Based Immunosuppression Is Associated With a Reduced Risk of New-Onset Malignancies After Liver Transplantation
P. De Simone,¹ P. Carrai,¹ L. Coletti,¹ D. Ghinolfi,¹ D. Campani,² F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy; ²Pathology, University of Pisa Medical School Hospital, Pisa, Italy.
Background and aim: The inhibitor of the mammalian target of rapamycin (mTOR) everolimus (EVR) has shown anti-proliferative effects in experimental and clinical models. We investigated…
2015 American Transplant Congress
Clinical Outcomes of Kidney Transplan Recipients After Sirolimus Or Everolimus Conversion. Experience in a Single Center
L. Mesa, E. Manzi, M. Valderrama, J. Posada, J. Schweineberg, C. Duran, G. Echeverri, J. Villegas, O. Serrano, L. Caicedo.
Transplant Unit, Fundación Valle del Lili, Cali, Colombia.
Introduction. The use of m_TOR inhibitors sirolimus (SRL) and everolimus (EVL), in kidney transplant recipients (KTR) is an alternative immunosuppressive therapy to reduce or withdrawal…